Literature DB >> 11455009

The noncompetitive inhibitor quinacrine modifies the desensitization kinetics of muscle acetylcholine receptors.

G Spitzmaul1, J P Dilger, C Bouzat.   

Abstract

Quinacrine has been shown to act as a noncompetitive inhibitor of the nicotinic acetylcholine receptor (nAChR). However, its mechanism of action is still a matter of controversy. We analyzed in detail the action of quinacrine at both the single-channel and macroscopic current levels. The main effect of quinacrine is a profound concentration-dependent decrease in both the frequency of opening events and the duration of clusters elicited by high acetylcholine concentrations. Quinacrine also significantly increases (40-fold at 30 microM) the decay rate of macroscopic currents elicited by rapid perfusion of acetylcholine to outside-out patches. This decay is still well-described by a single exponential. Quinacrine has very little effect on the peak amplitude of the response, suggesting that it acts mainly on open channels. The recovery from desensitization after removal of acetylcholine is delayed in the presence of quinacrine. Results from both single-channel and macroscopic current recordings indicate that quinacrine increases the rate of nAChR desensitization and stabilizes the desensitized state. Interestingly, in equilibrium agonist-binding assays, quinacrine does not promote the typical high-affinity desensitized state. Thus, quinacrine seems to induce an intermediate state exhibiting the permeability but not the agonist binding properties of desensitization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455009     DOI: 10.1124/mol.60.2.235

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  The interface between extracellular and transmembrane domains of homomeric Cys-loop receptors governs open-channel lifetime and rate of desensitization.

Authors:  Cecilia Bouzat; Mariana Bartos; Jeremías Corradi; Steven M Sine
Journal:  J Neurosci       Date:  2008-07-30       Impact factor: 6.167

Review 2.  Nicotinic acetylcholine receptors at the single-channel level.

Authors:  Cecilia Bouzat; Steven M Sine
Journal:  Br J Pharmacol       Date:  2017-04-08       Impact factor: 8.739

3.  Kinetics of desensitization and recovery from desensitization for human alpha4beta2-nicotinic acetylcholine receptors stably expressed in SH-EP1 cells.

Authors:  Kewei D Yu; Qiang Liu; Jie Wu; Ronald J Lukas
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

4.  The local anaesthetics proadifen and adiphenine inhibit nicotinic receptors by different molecular mechanisms.

Authors:  Guillermo Spitzmaul; Fernanda Gumilar; James P Dilger; Cecilia Bouzat
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

5.  Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states.

Authors:  Hugo R Arias; Fernanda Gumilar; Avraham Rosenberg; Katarzyna M Targowska-Duda; Dominik Feuerbach; Krzysztof Jozwiak; Ruin Moaddel; Irving W Wainer; Cecilia Bouzat
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

6.  Mechanism of tacrine block at adult human muscle nicotinic acetylcholine receptors.

Authors:  Richard J Prince; Richard A Pennington; Steven M Sine
Journal:  J Gen Physiol       Date:  2002-09       Impact factor: 4.086

7.  Glutamine 57 at the complementary binding site face is a key determinant of morantel selectivity for {alpha}7 nicotinic receptors.

Authors:  Mariana Bartos; Kerry L Price; Sarah C R Lummis; Cecilia Bouzat
Journal:  J Biol Chem       Date:  2009-06-08       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.